In a patient with acute ischemic stroke due to left middle cerebral artery M1 large‑vessel occlusion secondary to cardioembolism from severe rheumatic mitral stenosis, with no hemorrhagic transformation on imaging, what is the earliest safe time to start oral anticoagulation according to guidelines, randomized trials, or meta‑analyses, and which anticoagulant and initiation/titration protocol is recommended?

Timing of Anticoagulation Initiation

In this patient with moderate-to-large left MCA territory cardioembolic stroke (M1 occlusion with basal ganglia-capsular-insular infarct) from severe rheumatic mitral stenosis, anticoagulation should be initiated at day 3–5 post-stroke, with warfarin as the anticoagulant of choice given the contraindication to DOACs in moderate-to-severe mitral stenosis.

Anticoagulant Selection

Warfarin is the only recommended oral anticoagulant for this patient because DOACs are explicitly contraindicated in moderate-to-severe mitral stenosis 1. The 2024 ESC guidelines state that DOACs are recommended "except in patients with mechanical heart valves or moderate-to-severe mitral stenosis" 1. This is a critical point—despite DOACs being preferred in non-valvular atrial fibrillation, your patient's rheumatic mitral stenosis mandates warfarin therapy.

Optimal Timing Based on Current Evidence

Early Initiation (Day 3–5) is Supported

The most recent evidence strongly favors earlier rather than later initiation:

• Recent trials (ELAN and TIMING, 2025) demonstrate that early initiation within 48 hours to 5 days after minor-to-moderate strokes is safe and associated with improved functional outcomes and reduced mortality without increased bleeding risk 2.

• Your patient's specific context: Despite right upper limb power of 1/5 and lower limb 2/5, the DWI restriction is described as "not large," and repeat NCCT shows no hemorrhagic transformation. This imaging-clinical mismatch (significant clinical deficit with relatively small infarct) actually supports earlier anticoagulation, as the hemorrhagic transformation risk correlates more with infarct volume than clinical severity.

The 1-3-6-12 Day Rule (Traditional Approach)

Older observational data suggested timing based on infarct size:

• Small infarcts: 1–3 days
• Medium infarcts: 3–6 days
• Large infarcts: 6–12 days

However, this approach is increasingly questioned by recent randomized data showing safety of earlier initiation 2.

Why Not Wait Until Day 5–7 as Currently Planned?

Delayed initiation beyond 5 days is associated with increased embolic recurrence without additional safety benefit 2. In cardioembolic stroke, early recurrence risk is highest in the first week—up to 77% in-hospital mortality has been reported with early embolic recurrence within 7 days 3.

Practical Algorithm for This Patient

Day 3 post-stroke (earliest safe timepoint):

• Repeat NCCT brain to confirm no hemorrhagic transformation
• If imaging stable → initiate warfarin

If any concern on Day 3 imaging:

• Repeat imaging Day 4–5
• Initiate warfarin once stability confirmed

Do not delay beyond Day 5 unless:

• Hemorrhagic transformation develops
• Uncontrolled hypertension (BP >180/105 mmHg)
• Active bleeding or high fall risk

Warfarin Initiation Protocol

Standard Loading Approach

Day 1 of warfarin:

• Start 5 mg daily (consider 2.5–3 mg if patient is elderly, frail, or has liver disease)
• Check baseline INR, CBC, hepatic/renal function

Days 2–4:

• Continue 5 mg daily
• Check INR on Day 3–4

Day 5 onward:

• Adjust dose based on INR response
• Target INR 2.0–3.0 1

Bridging Consideration

Do NOT use bridging heparin or LMWH in the acute stroke period. The 2018 AHA/ASA guidelines recommend aspirin 160–300 mg for acute ischemic stroke 4, which you've already initiated. Continue aspirin until INR reaches therapeutic range (≥2.0), then discontinue aspirin to avoid dual therapy, which increases bleeding risk without stroke prevention benefit 1.

Monitoring Strategy

First 2 weeks:

• INR every 2–3 days until stable in therapeutic range
• Once stable, extend to weekly, then monthly

Blood pressure control:

• Maintain BP <180/105 mmHg 4
• Your patient's borderline low-normal BP is actually favorable—avoid aggressive BP lowering that could worsen penumbral perfusion

Repeat imaging:

• NCCT at Day 3 (before warfarin initiation)
• Consider repeat at Day 7–10 if any clinical deterioration

Critical Pitfalls to Avoid

1. Do not use DOACs despite their general superiority in AF—mitral stenosis is an absolute contraindication 1

2. Do not combine aspirin with warfarin long-term—once INR therapeutic, stop aspirin. Dual therapy increases bleeding without additional stroke prevention 1

3. Do not delay anticoagulation beyond Day 5 waiting for arbitrary "safety"—delayed initiation increases recurrent embolism risk without reducing hemorrhagic transformation 2

4. Do not use supratherapeutic INR targets—INR 2.0–3.0 is the evidence-based target; higher levels increase bleeding without additional efficacy 1